Back to Main

Faculty Detail     Name MARK N PRICHARD   Campus Address CHB 128 Zip 0011 Phone 205-934-1990 E-mail mprichar@uab.edu Other websites http://www.uab.edu/medicine/peds/macsynergy

Faculty Appointment(s) Appointment Type Department Division Rank Primary  Pediatrics   Ped - Infectious Disease Professor Secondary  Cell, Developmntl, & Integrative Biology  Cell, Developmntl, & Integrative Biology Professor Secondary  Microbiology  Microbiology Associate Professor Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor

Biographical Sketch  Dr. Prichard received his Ph.D. from the University of Michigan in the Department of Microbiology and Immunology. He did his postdoctoral training in the laboratory of Dr. Ed Mocarski at Stanford University. He then spent several years in the biotech industry and was involved in the development of Flumist while employed at MedImmune Vaccines Inc. He is a Professor of Pediatrics at the University of Alabama at Birmingham where he is also the Director of the Diagnostic Virology Laboratory. He is an Editor of the journal, Antiviral Research, and is coauthor of more than 80 publications, book chapters and review articles, as well as the MacSynergy II analytical software. Current research interests include the discovery of antiviral drugs for DNA viruses and defining their activity at the molecular level.

Society Memberships Organization Name Position Held Org Link American Society for Microbiology      American Society for Virology      Antiviral Congress  Scientific Committee  http://www.antivirals.elsevier.com/index.html  Antiviral Research  Editor  http://www.journals.elsevier.com/antiviral-research/  International Society for Antiviral Research  Board Member, Program Chair  http://www.isar-icar.com/

Research/Clinical Interest Title Antiviral drugs and their mechanism of action Description Studies in the lab focus on the discovery of new antiviral drugs for herpesviruses, orthopoxviruses, and papovaviruses. This work has identified a number of novel targets for antiviral therapy and help to characterize unrecognized aspects of viral replication.

Selected Publications  Publication PUBMEDID Stern-Ginossar, N., Elefant,N., Zimmermann, A., Wolf, D.G., Saleh, N., Biton, M., Horwitz, E., Prokocimer, Z., Prichard, M.N., Hahn, G., Goldman-Wohl, D., Greenfield, C., Yagel, S., Hengel, H., Altuvia, Y., Margalit, H., Mandelboim, O. 2007. Host immune system gene targeting by a viral miRNA. Science. 317: 376-381.  17641203  Prichard, M.N.*, Keith, K.A., Johnson M.P., Harden, E.A., McBrayer, A., Luo, M., Qiu, S., Chattopadhyay, D., Fan, X., Torrence, P.F., and Kern, E.R. 2007. Selective phosphorylation of antiviral drugs by the vaccinia virus thymidine kinase. Antimicrob. Agents Chemother. 51:1795–1803.  17325220  Prichard, M.N.*, Britt, W.J., Daily, S.L., Hartline, C.A., and Kern E.R. 2005. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79(24):15494-15502.:1.   16306620   Williams-Aziz, S.L., Hartline, C.B., Harden, E.A., Daily, S.M, Prichard, M.N., Kushner, N.L., Beadle, J.R., Wan, W.B., Hostetler, K.Y., and Kern, E.R. 2005. Comparative activity of ether lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49:3724-3733.  16127046  Prichard, M.N.*, Lawlor, H.A., Duke, G.W., Dixon, M.L., Wang, Z., Mo, C., Bidanset, D., Kemble, G.W., and Kern, E.R. 2005. Human cytomegalovirus uracil DNA glycosylase associates with ppUL44 and accelerates the accumulation of genomic DNA. Virol. J. 2:55.  16022730  Kreissel, J.D., Spruance, S.L., Prichard, M.N., Parker, J.N. and Kern, E.R. 2005. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J. Infect. Dis. 192(1):156-161.  15942905   Wolf, D.G., Courcelle, C.T., Prichard, M.N., and E.S.Mocarski. 2001. Distinct and separate roles of herpesvirus conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. U.S.A. 98: 1895-1900.   11172047   Prichard, M.N.*, N. Gao, S. Jairath, G. Mulamba, P. Krosky,D.M. Coen, B.O. Parker, and G.S. Pari. 1999. A Recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670.   10364316  Prichard MN*, Kern ER, Hartline CB, Lanier ER, Quenelle DC. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Antimicrob Agents Chemother. 2011;55(10):4728-34  3186990  James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Bowlin TL, Kern ER, and Prichard MN*. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother. 2011;55(10):4682-91  3186952  First Prev   1 2 of  2  Next Last

Keywords antiviral, vaccine, protein kinase, virology

© 2008 University of Alabama at Birmingham. All rights reserved. DisclaimerAbout this SiteGraphic Design Created by UAB Web Communications.
Calendar Designed by Medical Education Information Services. To report problems with the site, email us at meis@uab.edu. Last Revision: February 15, 2012.
The UAB School of Medicine Mailing Address: 1530 3rd Avenue South, FOT 1203, Birmingham AL 35294-3412